CCMB partners with Aganitha to apply GenAI for therapeutic research
Initial areas of collaboration include target analysis, small molecule design, and antibody and nanobody engineering for addressing malaria, TB
image for illustrative purpose
Hyderabad: The Centre for Cellular & Molecular Biology (CCMB) and Aganitha, a new generation 'in silico' solutions provider, signed a framework agreement to apply Generative Artificial Intelligence (AI) solutions for designing novel therapeutics and research tools addressing needs in multiple disease areas.
CCMB, a part of the Council of Scientific & Industrial Research (CSIR), and Aganitha, which combines the power of deep science and deep tech to bring novel medicines to market faster, signed an umbrella memorandum of understanding (MoU) to apply Aganitha’s Generative AI solutions for small molecule and antibody design for translation of CCMB’s R&D findings into therapeutic candidates.
Initial areas of collaboration include target analysis, small molecule design, and antibody and nanobody engineering for addressing malaria, tuberculosis (TB), and neurological disorders.
This strategic collaboration is designed to translate discoveries from the globally acclaimed research labs of CCMB into therapeutic candidates through the application of Aganitha’s Generative AI solutions for biopharma R&D, said a joint statement on Wednesday.
"We continue to struggle with controlling malaria due to drug resistance of the pathogen, lack of broadly available vaccines, and insecticide resistance of mosquitoes.
